Mirati Therapeutics, Inc.

( )
MRTX PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. 0.12%283.741.5%$847.25m
GILDGilead Sciences, Inc. 0.98%86.261.0%$795.01m
MRNAModerna, Inc. -0.23%176.400.0%$769.19m
VRTXVertex Pharmaceuticals, Inc. -1.01%312.981.9%$482.01m
REGNRegeneron Pharmaceuticals, Inc. 0.12%736.232.6%$473.28m
BIIBBiogen, Inc. 0.56%305.151.8%$355.07m
ILMNIllumina, Inc. -1.39%218.993.2%$270.73m
SNSSSunesis Pharmaceuticals, Inc. 5.70%2.780.7%$194.33m
BMRNBioMarin Pharmaceutical, Inc. -0.89%96.924.2%$161.47m
BNTXBioNTech SE -0.88%154.850.0%$152.12m
MRTXMirati Therapeutics, Inc. 2.89%98.621.6%$132.21m
TECHBio-Techne Corp. 0.79%338.974.5%$123.89m
AXSMAxsome Therapeutics, Inc. 1.07%56.821.6%$80.71m
NVAXNovavax, Inc. -2.88%16.5475.3%$70.44m
HALOHalozyme Therapeutics, Inc. 0.59%54.6718.4%$64.50m

Company Profile

Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA.